| Surviving the storm: Dealing with COVID-19 #MMPMID32563849Vandenbark AA; Meza-Romero R; Offner HCell Immunol 2020[Aug]; 354 (ä): 104153 PMID32563849show ga
ä|Anti-Inflammatory Agents/*pharmacology[MESH]|Antigens, Differentiation, B-Lymphocyte/immunology/metabolism[MESH]|Betacoronavirus/physiology[MESH]|COVID-19[MESH]|Coronavirus Infections/drug therapy/*immunology/*pathology[MESH]|Cytokine Release Syndrome/*drug therapy/pathology[MESH]|HLA-DR alpha-Chains/*genetics[MESH]|Histocompatibility Antigens Class II/immunology/metabolism[MESH]|Humans[MESH]|Myelin-Oligodendrocyte Glycoprotein/genetics[MESH]|Pandemics[MESH]|Pneumonia, Viral/drug therapy/*immunology/*pathology[MESH]|Receptors, Antigen, T-Cell/antagonists & inhibitors[MESH]|Recombinant Proteins/genetics/metabolism/*pharmacology[MESH]
DeepDyve Pubget Overpricing |
|